Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007811 | 0.87 | KDM4E (0.46) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4823620 | 0.86 | ALDH1A1 (0.45) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL18920757 | 0.84 | KDM4E (0.46) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL28239248 | 0.83 | ALDH1A1 (0.53) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4823733 | 0.82 | MEN1 (0.47) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4160348 | 0.82 | SLC6A4 (0.55) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4165566 | 0.82 | SMN1; SMN2 (0.45) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4821326 | 0.81 | SMN1; SMN2 (0.43) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4161772 | 0.80 | CCR5 (0.45) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6745160 | 0.80 | ALDH1A1 (0.54) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-6699873-B1 | EATING DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | KDM4E 1351/4885MEN1 320/4885ALDH1A1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.